St. Jude Medical, Inc. (NYSE: STJ) today reported sales and net
earnings for its second quarter ended July 4, 2015.
Second quarter 2015 highlights:
- Net sales increased by approximately 6
percent on a constant currency basis compared to the prior year
quarter
- CardioMEMS™ HF System sales totaled
approximately $20 million
- Atrial fibrillation revenue increased
by approximately 18 percent on a constant currency basis due to
global market share gains driven by the St. Jude Medical
FlexAbilityTM and TactiCathTM Quartz Contact Force ablation
catheters
- Worldwide neuromodulation revenue
increased by approximately 17 percent on a constant currency basis,
marking the fourth consecutive quarter of sales acceleration on a
year over year basis
Second Quarter 2015 Sales
The company reported net sales of $1.410 billion in the second
quarter of 2015, a 3 percent decrease compared to net sales of
$1.448 billion in the second quarter of 2014. On a constant
currency basis, net sales increased by approximately 6 percent
compared to the second quarter of 2014.
Commenting on the company’s financial results, St. Jude Medical
Chairman, President and Chief Executive Officer Daniel J. Starks
said, “St. Jude Medical’s second quarter results reflect the
continued success of our innovation-based growth strategy. We
remain confident in our key programs that accelerated sales growth
in the first half of 2015 and are raising our sales guidance in
order to demonstrate our strong outlook for the remainder of the
year."
Cardiac Rhythm Management (CRM)
Total CRM sales, which include implantable cardioverter
defibrillator (ICD) and pacemaker products, were $670 million for
the second quarter of 2015, a 9 percent decline compared to the
prior year quarter. After adjusting for the impact of foreign
currency, CRM sales decreased 1 percent compared to the prior year
quarter.
Of that total, ICD product sales were $421 million in the second
quarter, a 9 percent decline on a reported basis and decreased 2
percent on a constant currency basis compared to the prior year
quarter.
Second quarter pacemaker sales were $249 million, an 8 percent
decline compared to the prior year quarter. On a constant currency
basis, pacemaker product sales increased 1 percent compared to the
prior year quarter.
Atrial Fibrillation (AF)
AF product sales for the second quarter totaled $279 million, a
9 percent increase compared to the prior year quarter. On a
constant currency basis, AF product sales increased 18 percent
compared to the prior year quarter.
Cardiovascular
Total cardiovascular sales, which primarily include structural
heart and vascular products, were $343 million for the second
quarter of 2015, a 2 percent decline compared to the prior year
quarter. On a constant currency basis, cardiovascular sales
increased 7 percent compared to the prior year quarter.
Structural heart product sales for the second quarter of 2015
were $159 million, up 2 percent on a constant currency basis
compared to the prior year quarter.
Sales of vascular products in the second quarter of 2015 were
$184 million, a 12 percent increase on a constant currency basis
compared to the prior year quarter.
Neuromodulation
St. Jude Medical sales of neuromodulation products were $118
million in the second quarter of 2015, a 10 percent increase on a
reported basis and a 17 percent increase on a constant currency
basis compared to the prior year quarter.
Second Quarter Earnings Results
In the second quarter the Company recognized net after-tax
benefits of $20 million, or $0.07 per diluted share, primarily
related to acquisition-related adjustments, discrete income tax
benefits and ongoing restructuring activities. Including these
items, reported net earnings for the second quarter of 2015 were
$290 million or $1.02 per share, compared with reported net
earnings for the second quarter of 2014 of $270 million or $0.93
per share. Reported results also include the $17 million after-tax
impact, or $0.06 per diluted share, of amortization of intangible
assets.
In accordance with GAAP, reported net earnings for the second
quarter 2015 do not include any benefit from the federal research
and development tax credit, which has yet to be extended for 2015.
Including the benefit of this adjustment and excluding the second
quarter net credits and intangible amortization expense, adjusted
net earnings for the second quarter of 2015 were $293 million, or
$1.03 per share. A reconciliation of the Company’s non-GAAP
adjusted results to the Company’s GAAP reported results is provided
in the schedules at the end of the press release.
Third Quarter and Full-Year 2015 Sales and Earnings
Guidance
For the third quarter, St. Jude Medical expects revenue to grow
in the range of 5 percent to 7 percent on a constant currency basis
compared to the third quarter of 2014 with currency negatively
impacting third quarter revenue by approximately $105 million to
$115 million. For the full-year 2015, the company now expects total
revenue to grow in the range of 4 percent to 6 percent on a
constant currency basis with currency negatively impacting
full-year 2015 revenue by approximately $385 million to $410
million. During its earnings conference call today, St. Jude
Medical will provide an update to its range for revenue
expectations for the full-year 2015 by product category.
The company expects its consolidated adjusted net earnings for
the third quarter of 2015 to be in the range of $0.96 to $0.98 per
share and for full-year 2015 consolidated adjusted net earnings to
be in the range of $3.96 to $4.00. A further reconciliation of the
company’s quarterly and annual guidance is provided in the
schedules at the end of the press release.
Conference Call / Webcast
St. Jude Medical’s second quarter earnings call can be heard
live via webcast today beginning at 7 a.m. CT via the St. Jude
Medical Investor Relations website (investors.sjm.com).
Approximately one hour following the call (and archived for 90
days), a replay will be available on the Investor Events and
Presentations webpage in the Investor Relations section of the St.
Jude Medical website.
St. Jude Medical will also be tweeting live during the call on
our Investor Relations Twitter account, @StJudeMedicalIR.
About St. Jude Medical
St. Jude Medical is a global medical device manufacturer
dedicated to transforming the treatment of some of the world’s most
expensive epidemic diseases. The company does this by developing
cost-effective medical technologies that save and improve lives of
patients around the world. Headquartered in St. Paul, Minn., St.
Jude Medical has four major clinical focus areas that include
cardiac rhythm management, atrial fibrillation, cardiovascular and
neuromodulation. For more information, please visit sjm.com or
follow us on Twitter @StJudeMedicalIR.
Forward-Looking Statements
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties. Such forward-looking
statements include the expectations, plans and prospects for the
Company, including potential clinical successes, anticipated
regulatory approvals and future product launches, and projected
revenues, margins, earnings and market shares. The statements made
by the Company are based upon management’s current expectations and
are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include
market conditions and other factors beyond the Company’s control
and the risk factors and other cautionary statements described in
the Company’s filings with the SEC, including those described in
the Risk Factors and Cautionary Statements sections of the
Company’s Annual Report on Form 10-K for the fiscal year ended
January 3, 2015 and Quarterly Report on Form 10-Q for the fiscal
quarter ended April 4, 2015. The Company does not intend to update
these statements and undertakes no duty to any person to provide
any such update under any circumstance.
Summary of 2Q15 Sales and Reconciliation to Constant
Currency Sales Growth (in millions)
(unaudited)
Constant Constant
2Q15 Sales 2Q14 Sales Reported % Currency
%
Reported
Currency
Foreign Change vs. Change vs.
$ Change
$ Change
Currency
2Q14 2Q14
vs. 2Q14
vs. 2Q14
Impact Total Sales $1,410 $1,448
-3% 6% -$38 $80 -$118 Total
International Sales $697 $779 -10% 5%
Total U.S. Sales $713 $669 7%
Worldwide Cardiac
Rhythm Management $670 $733 -9% -1%
-$63 -$10 -$53 International Cardiac Rhythm
Management $300 $351 -14% 1% U.S.
Cardiac Rhythm Management $370 $382 -3%
Worldwide
ICD $421 $462 -9% -2% -$41
-$11 -$30 International ICD $156 $187
-17% -1% U.S. ICD $265 $275 -4%
Worldwide Pacemakers $249 $271 -8%
1% -$22 $1 -$23 International
Pacemakers $144 $164 -12% 2% U.S.
Pacemakers $105 $107 -2%
Worldwide Atrial
Fibrillation $279 $257 9% 18%
$22 $47 -$25 International Atrial Fibrillation
$159 $159 0% 15% U.S. Atrial
Fibrillation $120 $98 22%
Worldwide Cardiovascular
$343 $351 -2% 7% -$8 $25
-$33 International Cardiovascular $202 $233
-13% 1% U.S. Cardiovascular $141 $118
19%
Worldwide Structural Heart $159 $171
-7% 2% -$12 $4 -$16 International
Structural Heart $102 $116 -12% 1% U.S.
Structural Heart $57 $55 4%
Worldwide Vascular
$184 $180 2% 12% $4 $21
-$17 International Vascular $100 $117
-15% 0% U.S. Vascular $84 $63 32%
Worldwide Neuromodulation $118 $107 10%
17% $11 $18 -$7 International
Neuromodulation $36 $36 1% 21% U.S.
Neuromodulation $82 $71 15%
Note: Percentage
changes are based on actual, non-rounded amounts and may not
recalculate precisely.
St. Jude Medical, Inc.
Condensed Consolidated Balance Sheets (in millions)
(Unaudited) July 4, 2015
January 3, 2015 Cash and cash equivalents $910 $1,442
Accounts receivable, net 1,240 1,215 Inventories 817 784 Other
current assets 459 473 Property, plant & equipment, net 1,298
1,343 Goodwill 3,520 3,532 Other intangible assets, net 801 851
Other assets 589 567 Total assets $9,634 $10,207 Current
debt obligations $1,979 $1,593 Other current liabilities 1,035
1,073 Long-term debt 1,762 2,273 Long-term other liabilities 1,017
1,024 Total equity 3,841 4,244 Total liabilities & equity
$9,634 $10,207
St. Jude Medical, Inc.
Condensed Consolidated Statements of Earnings (in
millions, except per share amounts) (Unaudited)
Three
Months Ended Six Months Ended
July 4, 2015
June 28, 2014 July 4, 2015 June 28, 2014 Net
sales $1,410 $1,448 $2,755 $2,811 Cost of sales: Cost of sales
before special charges 419 407 812 789 Special charges 5 26 7 27
Total cost of sales 424 433 819 816 Gross profit 986 1,015 1,936
1,995 Selling, general & administrative expense 447 502
877 946 Research & development expense 171 178 338 348
Amortization of intangible assets 24 21 48 42 Special charges 30 25
34 58 Operating profit 314 289 639 601 Other expense, net 20 21 37
41 Earnings before noncontrolling interest and income taxes 294 268
602 560 Income taxes 12 22 64 75 Net earnings before noncontrolling
interest 282 246 538 485 Net loss attributable to noncontrolling
interest (8) (24) (14) (34) Net earnings attributable to St. Jude
Medical, Inc. $290 $270 $552 $519 Diluted net
earnings per share attributable to St. Jude Medical, Inc. $1.02
$0.93 $1.93 $1.80 Adjusted diluted net earnings per share
attributable to St. Jude Medical, Inc. (Non-GAAP) (1) $1.03 $1.07
$1.95 $2.07 Cash dividends declared per share $0.29 $0.27
$0.58 $0.54 Weighted average shares outstanding- diluted
285.5 288.9 286.3 289.1 (1) See accompanying reconciliation
tables.
Non-GAAP Financial Measures
Reconciliations (Unaudited)
Three Months Ended July 4, 2015
Earnings before Net earnings
Net loss
Diluted net
noncontrolling before
attributable to
Net earnings
earnings per share
interest and noncontrolling noncontrolling
attributable to St.
attributable to St.
Diluted EPS
(in millions, except per share amounts) income taxes Income
taxes Effective tax rate interest interest
Jude Medical, Inc.
Jude Medical, Inc.
growth rate
As reported (GAAP)
$ 294 $ 12
4.1 % $ 282 $ (8 )
$ 290 $ 1.02 10 %
Restructuring activities 36 11 25 - 25 0.09 Acquisition-related
costs (10 ) 1 (11 ) 4 (15 ) (0.05 ) Product field action costs and
litigation costs (1 ) - (1 ) - (1 ) 0.00 Amortization of intangible
assets 24 7 17 - 17 0.06 Discrete income tax benefits - 29 (29 ) -
(29 ) (0.10 ) R&D credit - (6 ) 6 - 6 0.02
As adjusted (Non-GAAP)
$ 343
$ 54 15.7
% $ 289 $
(4 ) $ 293
$ 1.03 -4 %
Unfavorable foreign currency impact vs. 2014 0.18
Constant currency as adjusted (non-GAAP)
$
1.21 13 %
Product field
Restructuring
Acquisition-
action costs and
activities
related costs
litigation costs Total Special charges (cost
of sales) $ 9 $ - $ (4 ) $ 5 Selling, general & administrative
expense - (11 ) - (11 ) Research & development expense - 1 - 1
Special charges (operating expenses) 27
- 3 30
$
36 $ (10 )
$ (1 ) $ 25
Three Months Ended June 28, 2014 Earnings
before Net earnings Net loss
Diluted net
noncontrolling before attributable to Net earnings
earnings per share
interest and noncontrolling noncontrolling attributable to St.
attributable to St. (in millions, except per share amounts) income
taxes Income taxes Effective tax rate interest
interest Jude Medical, Inc. Jude Medical, Inc.
As reported (GAAP)
$ 268 $ 22
8.2 % $ 246 $ (24
) $ 270 $ 0.93
Restructuring activities 60 18 42 - 42 0.15 Acquisition-related
costs 31 6 25 16 9 0.03 Product field action costs and litigation
costs 18 7 11 - 11 0.04 Legal settlements (27 ) (10 ) (17 ) - (17 )
(0.06 ) Amortization of intangible assets 21 8 13 - 13 0.04
Discrete income tax benefits - 24 (24 ) - (24 ) (0.08 ) R&D
credit - (4 ) 4 - 4 0.01
As adjusted
(Non-GAAP)
$ 371 $ 71
19.1 % $
300 $ (8 )
$ 308 $ 1.07
Product field
Restructuring
Acquisition-
action costs and
activities
related costs
litigation costs
Legal settlements
Total Special charges (cost of sales) $ 26 $ - $ - $
- $ 26 Selling, general & administrative expense - 31 - - 31
Special charges (operating expenses) 34
- 18 (27 )
25
$ 60 $ 31
$ 18 $ (27
) $ 82 Six Months
Ended July 4, 2015 Earnings before Net earnings Net
loss
Diluted net
noncontrolling before attributable to Net earnings
earnings per share
interest and noncontrolling noncontrolling attributable to St.
attributable to St.
Diluted EPS
(in millions, except per share amounts) income taxes Income
taxes Effective tax rate interest interest
Jude Medical, Inc. Jude Medical, Inc.
growth rate
As reported (GAAP)
$ 602 $ 64
10.6 % $ 538 $ (14
) $ 552 $ 1.93 7 %
Restructuring activities 49 14 35 - 35 0.12
Acquisition-related costs (32 ) 2 (34 ) 4 (38 ) (0.13 ) Product
field action costs and litigation costs 2 1 1 - 1 0.00 Legal
settlements (10 ) (4 ) (6 ) - (6 ) (0.02 ) Amortization of
intangible assets 48 15 33 - 33 0.12 Discrete income tax benefits -
29 (29 ) - (29 ) (0.10 ) R&D credit - (11 ) 11 - 11 0.04
As adjusted (Non-GAAP)
$
659 $ 110
16.7 % $ 549
$ (10 ) $ 559
$ 1.95 -6 %
Unfavorable foreign currency impact vs. 2014 0.33
Constant currency as adjusted (non-GAAP)
$
2.28 10 %
Product field
Restructuring
Acquisition-
action costs and
activities
related costs
litigation costs Legal settlements Total
Special charges (cost of sales) $ 13 $ - $ (6 ) $ - $ 7
Selling, general & administrative expense - (33 ) - - (33 )
Research & development expense - 1 - - 1 Special charges
(operating expenses) 36 -
8 (10 ) 34
$ 49 $ (32 )
$ 2 $ (10 )
$ 9 Six Months Ended June
28, 2014 Earnings before Net earnings Net loss
Diluted net
noncontrolling before attributable to Net earnings
earnings per share
interest and noncontrolling noncontrolling attributable to St.
attributable to St. (in millions, except per share amounts) income
taxes Income taxes Effective tax rate interest
interest Jude Medical, Inc. Jude Medical, Inc.
As reported (GAAP)
$ 560 $ 75
13.4 % $ 485 $ (34
) $ 519 $ 1.80
Restructuring activities 94 29 65 - 65 0.22 Acquisition-related
costs 33 6 27 16 11 0.04 Product field action costs and litigation
costs 18 7 11 - 11 0.04 Legal settlements (27 ) (10 ) (17 ) - (17 )
(0.06 ) Amortization of intangible assets 42 16 26 - 26 0.09
Discrete income tax benefits - 24 (24 ) - (24 ) (0.08 ) R&D
credit - (8 ) 8 - 8 0.03
As adjusted
(Non-GAAP)
$ 720 $ 139
19.3 % $
581 $ (18 )
$ 599 $ 2.07
Product field
Restructuring
Acquisition-
action costs and
activities
related costs
litigation costs Legal settlements Total
Special charges (cost of sales) $ 27 $ - $ - $ - $ 27
Selling, general & administrative expense - 33 - - 33 Special
charges (operating expenses) 67 -
18 (27 ) 58
$ 94 $ 33
$ 18 $ (27
) $ 118 The sum of
the components may not equal the total due to rounding and
quantities of shares outstanding in different periods. Tax
rates vary and are applied based on the item's nature and tax
jurisdiction where it is incurred.
2015 Earnings
Guidance Reconciliation (Unaudited)
Third Quarter Full Year Estimated 2015 diluted net
earnings per share attributable to St. Jude Medical,Inc. $0.84 -
$0.86 $3.70 - $3.74 Estimated restructuring activities 0.02 0.16
Estimated acquisition-related costs 0.02 (0.09) Legal settlements -
(0.02) Estimated amortization of intangible assets 0.06 0.23
Discrete income tax benefits - (0.10) Estimated R&D credit 0.02
0.08 Estimated 2015 adjusted diluted net earnings per share
attributable to St. Jude Medical, Inc. (Non-GAAP) $0.96 - $0.98
$3.96 - $4.00 The sum of the components may not equal the
total due to rounding and quantities of shares outstanding in
different periods.
2015 Sales Guidance
Reconciliation (in millions) (Unaudited)
Third Quarter Full Year 2014 total
sales $1,372 $5,622 Estimated 2015 sales $1,325 - $1,365 $5,435 -
$5,575 Estimated 2015 % change vs 2014 (3%) - (1%) (3%) - (1%)
Estimated unfavorable foreign currency impact vs 2014 $105 -
$115 $385 - $410 Estimated constant currency 2015 total sales
(Non-GAAP) $1,440 - $1,470 $5,845 - $5,960 Estimated 2015 constant
currency % change vs 2014 (Non-GAAP) 5% - 7% 4% - 6%
Non-GAAP Financial Measures
The company provides the following non-GAAP financial measures
because St. Jude Medical management believes that in order to
properly understand the company’s short-term and long-term
financial trends, investors may wish to consider the impact of
certain adjustments discussed below. St. Jude Medical management
uses these non-GAAP financial measures to forecast and evaluate the
operational performance of the company as well as to compare
results of current periods to prior periods on a consolidated
basis.
- Adjusted earnings before noncontrolling
interest and income taxes
- Adjusted income taxes and adjusted
effective tax rate
- Adjusted net earnings before
noncontrolling interest
- Adjusted net loss attributable to
noncontrolling interest
- Adjusted net earnings attributable to
St. Jude Medical, Inc.
- Adjusted diluted net earnings per share
attributable to St. Jude Medical, Inc. and adjusted diluted EPS
growth rate
- Adjusted constant currency diluted net
earnings per share attributable to St. Jude Medical, Inc. and
adjusted constant currency diluted EPS growth rate
The adjustments made to GAAP financial measures result from
facts and circumstances that vary in frequency and impact on the
Company’s results of operations. The following is an explanation of
each of the adjustments that management excludes in calculating its
non-GAAP measures.
Restructuring activities – These amounts represent severance
costs and other termination benefits, inventory write-offs
primarily associated with discontinued product lines, fixed asset
write-offs related to assets no longer expected to be utilized and
other restructuring costs.
Acquisition-related costs – These amounts consist of contingent
consideration fair value adjustments, acquired inventory step-up
amortization, other transaction costs and integration costs.
Product field action costs and litigation costs – These amounts
primarily relate to inventory write-off and disposal costs,
additional warranty and patient monitoring costs, and estimated
legal costs for outstanding legal matters associated with product
field actions.
Legal settlements – These amounts consist of losses that are
probable and reasonably estimable, gains related to favorable
resolutions of litigation matters and probable insurance
recoveries.
Amortization of intangible assets – These amounts represent the
non-cash amortization expenses we recognized for definite-lived
intangible assets.
Discrete income tax items – These amounts represent tax effects
related to significant unusual or infrequent items not attributable
to current-year ordinary income, such as settlement of tax
positions and discrete tax adjustments to uncertain tax
positions.
R&D credit – These amounts represent the impact of the
federal research and development tax credit to present comparative
periods assuming that the tax credit had been enacted in all
periods presented.
Foreign currency impact – These amounts represent the impact to
net sales and adjusted diluted net earnings per share attributable
to St. Jude Medical, Inc. after translating net sales and the
consolidated statement of earnings at comparable prior period
foreign currency exchange rates.
The company also provides constant currency sales growth and
constant currency adjusted EPS growth because St. Jude Medical
management believes that in order to properly understand the
Company’s short-term and long-term financial trends, investors may
wish to consider the impact of foreign currency translation on net
sales and adjusted EPS. St. Jude Medical management uses constant
currency sales growth and constant currency adjusted EPS growth to
forecast and evaluate the operational performance of the company as
well as to compare sales and adjusted EPS of current periods to
prior periods.
Non-GAAP financial measures used by the company may be
calculated differently from, and therefore may not be comparable
to, similarly titled measures used by other companies. Investors
should consider non-GAAP measures in addition to, and not as a
substitute for, or superior to, financial performance measures
prepared in accordance with GAAP.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150722005306/en/
St. Jude Medical, Inc.Media Contact:Kate Stoltenberg,
651-756-3388kstoltenberg@sjm.comorInvestor Contact:J.C. Weigelt,
651-756-4347jweigelt@sjm.com
SJM (NYSE:STJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Apr 2023 to Apr 2024